Literature DB >> 745811

Osseous metastases: radiographic monitoring of therapeutic response.

J J Lokich.   

Abstract

The application of standard radiographs (metastatic series) and radionuclide scanning in the serial evaluation of patients treated for metastatic osseous lesions is reviewed. False positive interpretations of bone scans are related to the inability to distinguish osteoblastic healing response from osteoblastic response to progressive tumor. False negative scans are uncommon and are related generally to symmetrical osteoblastic activity or to inadequate (subthreshold) osteoblastic response to tumor. Standard radiographs are preferable to bone scans in the serial evaluation of the effectiveness of therapy for osseous metastases in that anatomic quantitation of lesions as well as the dynamic evolution of lytic lesions to "blastic" healing may be appreciated. Serial bone scanning should be performed in conjunction with standard radiographs of abnormal areas of radionuclide accumulation.

Entities:  

Mesh:

Year:  1978        PMID: 745811     DOI: 10.1159/000225304

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

1.  Dual-energy CT-scan quantification of recalcification in osteolyses of the vertebral body due to mammary carcinomas in the course of antineoplastic treatment.

Authors:  W Crone-Münzebrock; U M Carl
Journal:  Clin Exp Metastasis       Date:  1990 Mar-Apr       Impact factor: 5.150

2.  Radiographic evaluation of therapeutic response in bony metastases of breast cancer.

Authors:  H I Libshitz; G N Hortobagyi
Journal:  Skeletal Radiol       Date:  1981       Impact factor: 2.199

3.  Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteria.

Authors:  Vito Amoroso; Frida Pittiani; Salvatore Grisanti; Francesca Valcamonico; Edda Simoncini; Vittorio D Ferrari; Giovanni Marini
Journal:  BMC Cancer       Date:  2007-06-01       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.